Healthcare and tech executives say it's possible for pharma to engage, use humor, and have fun on social media.
The Facebook for doctors launches Pages, allowing healthcare companies to establish a presence on Sermo and engage with physicians.
Technology executives discussed how pharma companies can leverage social media to better engage with patients online.
Social is a big deal in healthcare. Marketers can use it to create positive chatter and win greater awareness, recognition, and credibility among target audiences.
Curating personal relationships is one of the most valuable functions medical marketers can provide. The best way is through face-to-face interaction.
Part of LinkedIn's appeal lies in the high level of engagement of its members and the potential for precise targeting of content and talent searches.
Social listening can help all along the value chain—from research and discovery to developing marketing plans and strategy.
The company "embraces" adverse-event reporting and knows not to expect monetary ROI from unbranded initiatives, says its US-based social media lead.
Many patients allow doctors to access their social-media accounts; Turing will reportedly lower the price of Daraprim by 10%; WebMD reports boost in traffic
Work hard to get everyone in your company to understand what you can learn from social listening—you'll know you're successful when inquisitive minds throughout the company start asking you the question, "Can we find out what patients are saying about this brand online?"
An analysis conducted by J&J executives found that 58% of FDA warning letters and untitled letters over the last two years omitted risk information.
The drugmaker launched its first YouTube channel as it kicked off the campaign.
Stakeholder activists, social media and an increasingly global market are three defining issues for companies operating in the 21st century.
Pharma has hidden behind the ability to turn commenting off on Facebook pages, allowing marketers to use the channel much as they would a typical web page.
Kim Kardashian posts corrective information on Instagram and Twitter; DPP-4 inhibitors are linked to joint pain; doctors question off-label prescriptions of PCSK9 inhibitors
While social media can be a tool for pharma to help educate the public, it has also become a forum for the public to express their views about pharma, and it's not always flattering, as evidenced by the recent antivaccine movement.
The FDA said Kim Kardashian West's promotion of morning-sickness pill Diclegis misbranded the product by understating its risks.
From evolving healthcare laws to social engagement, litigation crises to media relations, McKesson's PR chief is hands-on in efforts to enhance the brand's image.
The pharma business needs to take engagement far more seriously than it has in the past. At the same time, there are signs that the industry is finally acting with more urgency and even transparency.
The consumer-insights firm said it's debuting a listening feature that will make it harder for pharma to ignore Twitter, Reddit and the other big social platforms.
Its alliance with the Society of Hospital Medicine will expand the network's reach among medical professionals.
The three-year-old campaign's youthful tone evolves as its audience ages.
Rep. Billy Long introduced legislation that is meant to push the FDA to implement clearer guidelines for regulating drug product information on social media.
Researchers say Twitter could provide critical insight into health needs for hard-to-reach groups.
Successful social-media engagement is not about the perfect picture or a tightly controlled brand. Instead, panelists at the Hub Convene conference indicated it's a matter of letting the audience take hold
A group of computer science and engineering students at the Carlos III Universidad in Madrid used natural language processing techniques to translate social-media and forum posts into adverse drug reaction data.
A look at the content that grabbed most reader interest over the past year.
The ACLU is among those questioning the positives of the rumored healthcare effort.
The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.
The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.
Click here to learn about the Agency Issue.
- When it comes to professional ads, print makes its comeback
- Amgen takes issue with yet-to-be published multiple-myeloma drug report
- How Watson for Oncology is advancing cancer care
- Following positive outcomes data, a new diabetes class is on the rise
- Creative partners should push pharma clients to tell better stories